Company
Headquarters: Taipei City, Taiwan
TW$4.80 Billion
TWD as of Jan. 1, 2026
US$153.2 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic products. The company is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. BioGend Therapeutics Co., Ltd. was founded in 2016 and is based in Taipei, Taiwan.
BioGend Therapeutics Co. Ltd has the following listings and related stock indices.
Stock: TWSE: 6733